Apremilast reduces co-occurring alcohol drinking and mechanical allodynia and regulates central amygdala GABAergic transmission. JCI Insight , 2025; 10 (8) DOI: 10.1172/jci.insight.189732 Cite ...

The results, published in JCI Insight on April 22, 2025, suggest that the drug apremilast-a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation-could ...

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

Ustekinumab also offers a durable response ... offer safety improvements and cost savings over biologics. Celgene's apremilast is an oral agent with several targets, including phosphodiesterase ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

They compared the risk for IBD between patients with psoriasis or ankylosing spondylitis who initiated IL-17A inhibitors and those who initiated apremilast between January 2015 and December 2024.

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

Get Instant Summarized Text (Gist) Apremilast, an FDA-approved phosphodiesterase-4 inhibitor, reduces both alcohol intake and pain sensitivity in rat models of alcohol use disorder. Its effects ...